Literature DB >> 31520407

The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH.

Rohit Loomba1,2, Leon A Adams3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31520407      PMCID： PMC7504908          DOI： 10.1002/hep.30946

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.298


× No keyword cloud information.
  10 in total

1.  Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.

Authors:  Eduardo Vilar-Gomez; Luis Calzadilla-Bertot; Vincent Wai-Sun Wong; Marlen Castellanos; Rocio Aller-de la Fuente; Mayada Metwally; Mohammed Eslam; Licet Gonzalez-Fabian; María Alvarez-Quiñones Sanz; Antonio Felix Conde-Martin; Bastiaan De Boer; Duncan McLeod; Anthony Wing Hung Chan; Naga Chalasani; Jacob George; Leon A Adams; Manuel Romero-Gomez
Journal:  Gastroenterology       Date:  2018-05-05       Impact factor: 22.682

2.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Paul Angulo; David E Kleiner; Sanne Dam-Larsen; Leon A Adams; Einar S Bjornsson; Phunchai Charatcharoenwitthaya; Peter R Mills; Jill C Keach; Heather D Lafferty; Alisha Stahler; Svanhildur Haflidadottir; Flemming Bendtsen
Journal:  Gastroenterology       Date:  2015-04-29       Impact factor: 22.682

Review 3.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.

Authors:  Siddharth Singh; Alina M Allen; Zhen Wang; Larry J Prokop; Mohammad H Murad; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2014-04-24       Impact factor: 11.382

4.  Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.

Authors:  Mohammad Shadab Siddiqui; Goro Yamada; Raj Vuppalanchi; Mark Van Natta; Rohit Loomba; Cynthia Guy; Danielle Brandman; James Tonascia; Naga Chalasani; Brent Neuschwander-Tetri; Arun J Sanyal
Journal:  Clin Gastroenterol Hepatol       Date:  2019-01-04       Impact factor: 11.382

5.  The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials.

Authors:  Arun J Sanyal; Stephen A Harrison; Vlad Ratziu; Manal F Abdelmalek; Anna Mae Diehl; Stephen Caldwell; Mitchell L Shiffman; Raul Aguilar Schall; Catherine Jia; Bryan McColgan; C Stephen Djedjos; John G McHutchison; G Mani Subramanian; Robert P Myers; Zobair Younossi; Andrew J Muir; Nezam H Afdhal; Jaime Bosch; Zachary Goodman
Journal:  Hepatology       Date:  2019-05-28       Impact factor: 17.425

6.  Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C.

Authors:  Jason M Hui; James G Kench; Shivakumar Chitturi; Archana Sud; Geoffrey C Farrell; Karen Byth; Pauline Hall; Mahbub Khan; Jacob George
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

Review 7.  Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

Authors:  Zobair M Younossi; Aaron B Koenig; Dinan Abdelatif; Yousef Fazel; Linda Henry; Mark Wymer
Journal:  Hepatology       Date:  2016-02-22       Impact factor: 17.425

8.  Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis.

Authors:  Naga Chalasani; Manal F Abdelmalek; Rohit Loomba; Kris V Kowdley; Arthur J McCullough; Srinivasan Dasarathy; Brent A Neuschwander-Tetri; Norah Terrault; Beatrice Ferguson; Reshma Shringarpure; David Shapiro; Arun J Sanyal
Journal:  Liver Int       Date:  2019-02-21       Impact factor: 5.828

9.  Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.

Authors:  Stephen A Harrison; Manal F Abdelmalek; Stephen Caldwell; Mitchell L Shiffman; Anna Mae Diehl; Reem Ghalib; Eric J Lawitz; Don C Rockey; Raul Aguilar Schall; Catherine Jia; Bryan J McColgan; John G McHutchison; G Mani Subramanian; Robert P Myers; Zobair Younossi; Vlad Ratziu; Andrew J Muir; Nezam H Afdhal; Zachary Goodman; Jaime Bosch; Arun J Sanyal
Journal:  Gastroenterology       Date:  2018-07-07       Impact factor: 22.682

10.  NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances.

Authors:  Mazen Noureddin; Aarshi Vipani; Catherine Bresee; Tsuyoshi Todo; Irene K Kim; Naim Alkhouri; Veronica Wendy Setiawan; Tram Tran; Walid S Ayoub; Shelly C Lu; Andrew S Klein; Vinay Sundaram; Nicholas N Nissen
Journal:  Am J Gastroenterol       Date:  2018-06-08       Impact factor: 12.045
  10 in total
  16 in total

Review 1.  AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review.

Authors:  Rohit Loomba; Joseph K Lim; Heather Patton; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2020-01-30       Impact factor: 22.682

Review 2.  The Role of Innate Immune Cells in Nonalcoholic Fatty Liver Disease.

Authors:  Marina Nati; Kyoung-Jin Chung; Triantafyllos Chavakis
Journal:  J Innate Immun       Date:  2021-08-24       Impact factor: 7.349

3.  The fecal mycobiome in non-alcoholic fatty liver disease.

Authors:  Münevver Demir; Sonja Lang; Phillipp Hartmann; Yi Duan; Anna Martin; Yukiko Miyamoto; Marina Bondareva; Xinlian Zhang; Yanhan Wang; Philipp Kasper; Corinna Bang; Christoph Roderburg; Frank Tacke; Hans-Michael Steffen; Tobias Goeser; Andrey Kruglov; Lars Eckmann; Peter Stärkel; Derrick E Fouts; Bernd Schnabl
Journal:  J Hepatol       Date:  2021-12-10       Impact factor: 25.083

4.  Non-alcoholic fatty liver disease.

Authors:  Wenhao Li; William Alazawi
Journal:  Clin Med (Lond)       Date:  2020-09       Impact factor: 2.659

Review 5.  Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future.

Authors:  Sonja Lang; Bernd Schnabl
Journal:  Cell Host Microbe       Date:  2020-08-12       Impact factor: 21.023

6.  Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease.

Authors:  Jung Gil Park; Jinho Jung; Kritin K Verma; Min Kyu Kang; Egbert Madamba; Scarlett Lopez; Aed Qas Yonan; Amy Liu; Ricki Bettencourt; Claude Sirlin; Rohit Loomba
Journal:  Aliment Pharmacol Ther       Date:  2021-03-25       Impact factor: 8.171

Review 7.  Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC.

Authors:  Hyunmi Kim; Da Som Lee; Tae Hyeon An; Hyun-Ju Park; Won Kon Kim; Kwang-Hee Bae; Kyoung-Jin Oh
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

8.  The incidence trends of liver cirrhosis caused by nonalcoholic steatohepatitis via the GBD study 2017.

Authors:  Mimi Zhai; Zhide Liu; Jianhai Long; Qingxiang Zhou; Leping Yang; Qin Zhou; Sushun Liu; Yu Dai
Journal:  Sci Rep       Date:  2021-03-04       Impact factor: 4.379

9.  Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy-proven non-alcoholic fatty liver disease.

Authors:  Sonja Lang; Anna Martin; Xinlian Zhang; Fedja Farowski; Hilmar Wisplinghoff; Maria J G T Vehreschild; Marcin Krawczyk; Angela Nowag; Anne Kretzschmar; Claus Scholz; Philipp Kasper; Christoph Roderburg; Raphael Mohr; Frank Lammert; Frank Tacke; Bernd Schnabl; Tobias Goeser; Hans-Michael Steffen; Münevver Demir
Journal:  Liver Int       Date:  2021-05-07       Impact factor: 8.754

Review 10.  NAFLD and cardiovascular diseases: a clinical review.

Authors:  Philipp Kasper; Anna Martin; Sonja Lang; Fabian Kütting; Tobias Goeser; Münevver Demir; Hans-Michael Steffen
Journal:  Clin Res Cardiol       Date:  2020-07-21       Impact factor: 5.460
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.